ArticlePDF Available

Abstract and Figures

The protective effects of cannabidiol (CBD) have been widely shown in preclinical models and have translated into medicines for the treatment of multiple sclerosis and epilepsy. However, the direct vascular effects of CBD in humans are unknown. Using wire myography, the vascular effects of CBD were assessed in human mesenteric arteries, and the mechanisms of action probed pharmacologically. CBD-induced intracellular signalling was characterised using human aortic endothelial cells (HAECs). CBD caused acute, non-recoverable vasorelaxation of human mesenteric arteries with an Rmax of ∼40%. This was inhibited by cannabinoid receptor 1 (CB1) receptor antagonists, desensitisation of transient receptor potential channels using capsaicin, removal of the endothelium, and inhibition of potassium efflux. There was no role for cannabinoid receptor-2 (CB2) receptor, peroxisome proliferator activated receptor (PPAR)γ, the novel endothelial cannabinoid receptor (CBe), or cyclooxygenase. CBD-induced vasorelaxation was blunted in males, and in patients with type 2 diabetes or hypercholesterolemia. In HAECs, CBD significantly reduced phosphorylated JNK, NFκB, p70s6K and STAT5, and significantly increased phosphorylated CREB, ERK1/2 and Akt levels. CBD also increased phosphorylated eNOS (ser1177), which was correlated with increased levels of ERK1/2 and Akt levels. High glucose prevented the increase in eNOS phosphorylation. This study shows, for the first time, that CBD causes vasorelaxation of human mesenteric arteries via activation of CB1 and TRP channels, and is endothelium- and nitric oxide-dependent. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email:
Content may be subject to copyright.
Cannabidiol causes endothelium-dependent
vasorelaxation of human mesenteric arteries
via CB
Christopher P. Stanley, William H. Hind, Cristina Tufarelli, and Saoirse E. O’Sullivan*
School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK
Received 4 September 2014; revised 20 May 2015; accepted 12 June 2015
Time for primary review: 41 days
Aims The protective effects of cannabidiol (CBD) have been widely shown in preclinical models and have translated into
medicines for the treatment of multiple sclerosis and epilepsy. However, the direct vascular effects of CBD in humans
are unknown.
and results
Using wire myography, the vascular effects of CBD were assessed in human mesenteric arteries, and the mechanisms of
action probed pharmacologically. CBD-induced intracellular signalling was characterizedusing human aortic endothelial
cells (HAECs). CBD caused acute, non-recoverable vasorelaxation of human mesenteric arteries with an R
40%. This was inhibited by cannabinoid receptor 1 (CB
) receptor antagonists, desensitization of transient receptor
potential channels using capsaicin, removal of the endothelium, and inhibition of potassium efflux. There was no role for
cannabinoid receptor-2 (CB
) receptor, peroxisome proliferator activated receptor (PPAR)g, the novel endothelial
cannabinoid receptor (CB
), or cyclooxygenase. CBD-induced vasorelaxation was blunted in males, and in patients
with type 2 diabetes or hypercholesterolemia. In HAECs, CBD significantly reduced phosphorylated JNK, NFkB,
p70s6 K and STAT5, and significantly increased phosphorylated CREB, ERK1/2, and Akt levels. CBD also increased
phosphorylated eNOS (ser1177), which was correlated with increased levels of ERK1/2 and Akt levels. CB
antagonism prevented the increase in eNOS phosphorylation.
Conclusion This study shows, for the first time, that CBD causes vasorelaxation of human mesenteric arteries via activation of CB
and TRP channels, and is endothelium- and nitric oxide-dependent.
Keywords Vasorelaxation Human Cannabidiol Cannabinoid Endothelium
1. Introduction
Numerous studies have shown that endogenous, synthetic, and plant-
derived cannabinoids cause vasorelaxation of a range of animal and
human arterial beds.
The extent of cannabinoid-induced vasorelaxa-
tion and the mechanisms involved often differs between the cannabin-
oid compound studied, the arterial bed used, and the species
employed. These mechanisms include activation of cannabinoid recep-
tor one (CB
), cannabinoid receptor two (CB
), transient receptor
potential vanilloid one (TRPV1), peroxisome proliferator activated re-
ceptor gamma (PPARg), and an as yet unidentified endothelial-bound
cannabinoid receptor (CB
Vasorelaxant mediators implicated in
cannabinoid-induced vasorelaxation include nitric oxide production,
prostaglandin production, metabolite production, and ion channel
modulation, some of which have been shown to be coupled to recep-
tor activation.
Cannabidiol (CBD) is a naturally occurring molecule found in the plant
Cannabis sativa. Unlike the related molecule D
(THC), it does not activate CB
receptors in the brain, and is devoid
of the psychotropic actions of THC. Indeed, CBD may antagonize
the psychoses associated with cannabis abuse.
Other receptor sites
implicated in the actions of CBD include the orphan G-protein-coupled
receptor GPR55, the putative endothelial cannabinoid receptor (CB
the transient receptor potential vanilloid 1 (TRPV1) receptor,
a1-adrenoceptors, mopioid receptors and 5-HT
CBD/THC combination (1 : 1 ratio, Sativex/Nabiximols) is currently
licensed internationally in more than 20 countries for the treatment
of spasticity in multiple sclerosis, and an as yet unlicensed CBD alone
*Corresponding author. Email:
&The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Cardiovascular Research
Cardiovascular Research Advance Access published June 30, 2015
by guest on July 7, 2015Downloaded from
product (Epidiolex) has entered an expanded access programme
in children with intractable epilepsies. CBD has also received orphan
designation status in treating newborn children with neonatal
hypoxic-ischaemic encephalopathy.
In addition to the licensed indications, preclinical evidence suggests
CBD has therapeutic potential in diseases associated with inflamma-
tion, oxidative stress, gastrointestinal disturbances, neurodegeneration,
cancer, diabetes, and nociception.
In the cardiovascular system,
CBD treatment in vivo reduces endothelial and cardiac dysfunction in
cardiomyopathy associated with diabetes.
CBD also reduces vas-
cular inflammation associated with endotoxic shock,
has a protective
role in diabetic retinopathy,
and is cardioprotective after coronary ar-
tery ligation.
Furthermore, CBD reduces infarct size and increases
cerebral blood flow in a mouse model of stroke when delivered either
pre- or post-ischaemia through activation of 5-HT
16 19
Unlike other cannabinoids, the direct vascular effects of CBD have
not been fully investigated in either animal or human studies.
et al.
showed that CBD (10 mmol/L) had no effect on vascular
tone in the perfused mesenteric arterial bed of mice. However, Offer-
taler et al.
reported that CBD caused a concentration-dependent
near maximal vasorelaxation of isolated rat mesenteric arteries, but
no mechanisms of action were probed. In the rat isolated aorta, we
showed that CBD causes a time-dependant vasorelaxant response
that was inhibited by antagonism of the PPARgreceptor and inhibition
of superoxide dismutase.
In light of the increasing evidence that CBD has beneficial effects on
the cardiovascular system, and since the vascular effects of CBD remain
to be characterized in human vasculature, the aim of the present study
was to establish the acute vascular effects of CBD in human arteries and
to underpin the pharmacology behind any potential response.
2. Methods
Ethical approval was granted by the Derbyshire Research Ethics Committee
and Derbyshire Hospitals Trust Research and Development to take mesen-
teric tissue from patients (27 males, 10 females) undergoing colorectal sur-
gery. Informed consent was gained in accordance with the Declaration of
Helsinki. Mesenteric arteries have been extensively used to characterize
the pharmacological effects of cannabinoids.
Excised mesenteric tissue
was placed in physiological saline solution (PSS) and transported back to
the lab. Arteries (701 +42 mmdiameter,mean+SEM) were dissected
from mesenteric tissue, cleaned of any adherent fatty and connective tissue
and cut into 2 mm segments. Artery segments were either used fresh or
after overnight storage in PSS at 48C. Overnight storage had no significant
effect on the contractile or relaxation responses of mesenteric arteries (see
Supplementary material online, Figure S1). Artery segments were mounted
on tungsten wires on a Mulvany-Halpern myograph (Danish Myo Technol-
ogy, Denmark) at 378C in PSS solution and gassed with 5% CO
in O
. Ten-
sion was measured using isometric force displacement transducers and
recorded using Chart 5 Pro (ADinstruments, Oxfordshire, UK). Using nor-
malization software, arteries were set to an internal diameter producing
90 mmHg pressure. To establish artery viability, the ability of arteries to
contract to high potassium PSS (KPSS) (composition, mmol/L: NaCl 0,
KCl 124, CaCl
25, KH
1.18, C
0.027, C
5.5 all dissolved in triple distilled water)
or to contract to U46619 (.5 mM), and to relax to 10 mmol/L bradykinin
(.70% relaxation) was measured.
2.1 Experimental protocol
Viable arteries were contracted using a combination of U46619 (50–
250 nmol/L) and Endothelin-1 (1– 3 nmol/L). Once a stable contraction
.5 mN was achieved, cumulative concentration –response curves were
constructed to CBD. CBD was added in 5-min intervals with measure-
ments taken in the final minute of each concentration addition and ex-
pressed as percentage relaxation of pre-imposed tone. Responses were
compared with ethanol-treated vehicle controls carried out in adjacent
arterial segments from the same patient. To characterize mechanisms
underpinning CBD-induced vasorelaxation, all interventions were com-
pared with a CBD controlresponse carried out in adjacent arteries
moved by abrasion using a human hair. A role for the involvement of nitric
oxide was investigated using NG-nitro-L-arginine methyl ester (L-NAME,
300 mmol/L, present throughout). A role for cyclooxygenase (COX) was
assessed using indomethacin (10 mmol/L, present throughout). A potential
role for potassium channel hyperpolarization was investigated by carrying
out concentration response curves to CBD in arteries contracted using
KPSS to inhibit potassium efflux. Potential cannabinoid receptor involve-
ment in CBD-induced vasorelaxation was assessed with CB
(AM251, 100 nmol/L or LY320135 1 mmol/L), CB
receptor antagonist
AM630 (100 nmol/L), or proposed endothelial cannabinoid receptor
, O1918, 10 mmol/L). Desensitization of sensory nerves was achieved
via incubation (1 h) with capsaicin (10 mmol/L) followed by three washouts
in PSS. In experiments to establish the potential location of the CB
tor, the effects of AM251 in endothelial-denuded arteries were compared
with arteries that were endothelial denuded only, arteries treated with
AM251 only and CBD control arteries. In each of these protocols, there
was no significant difference in the level of contraction immediately before
the CBD concentration response curve.
2.2 Cell culture
Human aortic endothelial cells (PromoCell, Germany, passage 4) were
grown in PromoCell Endothelial Cell Growth medium to confluence on
6-well plates and treated for 10 min with increasing concentrations of
CBD, after which time the medium was removed and the cells collected
in cell lysis buffer (RIPA buffer, SigmaAldrich) with phosphatase and prote-
ase inhibitors (Roche). Some experiments were performed in the presence
of AM251 or capsazepine. The protein concentration of the cell lysate was
measured using a BCA assay (BCA-1KT, SigmaAldrich). The levels of phos-
phorylated ERK/MAP kinase 1/2 (Thr185/Tyr187), Akt (Ser473), STAT3
(Ser727), JNK (Thr183/Tyr185), p70 S6 kinase (Thr412), NFkB (Ser536),
STAT5A/B (Tyr694/699), CREB (Ser133), and p38 (Thr180/Tyr182)
were measured in cell lysates using the LuminexwxMAP
technology using
a commercially available panel (MilliplexTM, 48-680MAG, Merck Millipore),
and normalized to total protein content. eNOS phosphorylation was mea-
sured using a PathScan Phospho-eNOS (ser1177) sandwich ELISA accord-
ing to the manufacturer’s instructions (Cell Signaling Technology, USA), and
was normalized to total protein content.
2.3 Reverse transcription-polymerase chain
The presence of target sites of action was investigated at the mRNA level
using reverse transcription followed by polymerase chain reaction
(RT-PCR) under control conditions, and in the presence of a high glucose
(25 mM) or high insulin (500 nM) medium for 96 h. Human astrocytes
(HAs) were used as a positive control known to express all the target sites
of action of interest.
Total RNA was extracted from HAs and HAECs
using Allprep DNA/RNA kit with on column DNaseI treatment (Qiagen,
Germany). Reverse transcription with and without reverse transcriptase
was performed in 30 ml final volume using 3 mg of total RNA and random
primers with the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, UK) according to the manufacturer’s instructions. PCRs
were carried out in a final volume of 25 ml with Zymotaq (ZymoResearch,
USA) using 2 ml of reverse transcription product as the template. Primer
pairs used to amplify 128 bp of the control house-keeping gene
C.P. Stanley et al.Page 2 of 11
by guest on July 7, 2015Downloaded from
Hypoxanthine-guanine PhosphoRibosylTransferase (HPRT) were from ref.
24; those for 99 bp PPARaand 87 bp PPARgwere from ref. 25; those for
303 bp CB1R and 365 bp CB2R were from ref. 26; those for 511 bp TRPV1
were from ref. 27; and finally the 380 bp calcitonin gene-related peptide
(CGRP) receptor (CGRPR) cDNA fragment was amplified using the pri-
mers reported in ref. 28. After 5 min at 958C, PCRs were performed for
40 cycles except those for CB2R that was carried out for 50 cycles. The
cycles included 30 s at 958C, 30 s at the annealing temperature that was op-
timal for each primer pair (568C for CB1R and CB2R; 608C for all others)
and a final extension step of 30 s at 728C. Amplification products were se-
parated by gel electrophoresis through ethidium bromide stained 2% agar-
ose (CB1R, CB2R, TRPV1, CGRPR) and 3% NuSieve 3:1 (PPARa, PPARg
and HPRT) and visualized using a Biorad Chemidoc.
2.4 Statistical analysis
Graphs represent mean percentage relaxations, with error bars represent-
ing the standard error of the mean (SEM) fit to non-linear Regression
(Curve Fit) (Prism Version 6; GraphPad Software, CA, USA). nrepresents
the number of arteries from patients. Comparisons between intervention
and control artery segments from the same patient were made using R
(the calculated maximal response to CBD) and EC
(potency of CBD)
compared by Student’s t-test. In experiments to assess the location of
the CB
receptor, comparisons were made between artery segments
from the same patient using one way analysis of variance (ANOVA) with
Dunnetts post-hoc analysis. Significance was determined as P,0.05.
2.5 Chemicals
All salts, L-NAME, indomethacin and bradykinin were supplied by Sigma
Chemical Co. (Poole, UK). AM251, LY 320135, AM630, and capsaicin
were purchased from Tocris (Bristol, UK). CBD was a kind gift from GW
Pharmaceuticals (Wiltshire, UK). L-NAME and indomethacin were dis-
solved in PSS solution. CBD, bradykinin, and capsaicin were all dissolved
in ethanol at 10 mM with further dilutions made in distilled water.
AM251, LY320135, and AM630 were dissolved in DMSO at 10 mmol/L
with further dilutions made in distilled water.
3. Results
Thirty-four patients (24 males and 10 females) were recruited for this
study. Twenty-seven had cancer and 7 had inflammatory bowel
disorder. A summary of patient characteristics, medical history, and
medications is presented in Table 1.
CBD caused vasorelaxation of pre-constricted human mesenteric
arteries with an R
of around 40% vasorelaxation (R
compared with vehicle control, n¼12, Figure 1Aand C,Table 2). For
comparison, the vasorelaxant response to 10 mmol/L bradykinin
(83 +3(mean+SEM) % relaxation) in the same patients is repre-
sented in Figure 1C. When added to un-contracted arteries, CBD had
no effect on baseline tone (n¼6, representative raw trace shown in
Figure 1A). In time-dependent experiments, a single concentration of
10 mmol/L CBD caused an initial vasorelaxation of 57 +4% relaxation
at 15 min, developing to 78 +7% at 120 min (P,0.001, n¼6,
Figure 1D).
Removal of the endothelium significantly reduced the potency
) of CBD (P,0.0001, Figure 2A,Table 2). The maximum vasore-
laxation to CBD also correlated positively with the endothelium-
dependent bradykinin response in patients (r¼0.394, P¼0.0158,
Figure 2B). Inhibition of COX activity using indomethacin had no effect
on the CBD-induced vasorelaxation (n¼6, Figure 2C). In arteries
Table 1 Patient characteristics, diagnosis, and
Characteristic Range Mean +++++ SEM
Ethnicity 34 UK white
Male 24
Female 10
Age 36 –82 65 +2.1
Weight (kg) 52 –126 76 +3
BMI (kg/m
) 17.5 –36.4 27.1 +0.7
Vessel size (mm) 346– 1372 701 +42
Bradykinin response (% relaxation) 70 –109 85 +1.4
Smoking habits
Non-smokers 28
0–10 CPD 3
10– 20 CPD 3
Drinking habits
,10 units p/w 23
10– 20 units p/w 7
.20 units p/w 4
Right hemicolectomy 10
Left hemicolectomy 7
Sigmoid colectomy 5
Anterior resection 10
Abdominoperineal resection 1
Total colectomy 1
Reason for surgery
Cancer 27
Inflammatory bowel disorder 7
Dukes Staging
Dukes A 10
Dukes B 9
Dukes C 8
Dukes D 0
Systolic blood pressure (mm/Hg) 110 –188 143+3
Diastolic blood pressure (mm/Hg) 62 –101 82 +1
Diabetic 10
Heart disease 9
Heart failure 0
Hypercholesterolemia 15
Hypertensive 16
a-1-adrenoceptor antagonist 3
ACE inhibitors 7
AT1 receptor antagonists 2
Beta-blockers 6
Calcium-channel blocker 3
Digoxin 2
Diuretics 3
Hypoglycaemic medication 6
Nsaid medication 14
Statin 14
Thiazolidinedione 1
CBD Induced vasorelaxation of human arteries Page 3 of 11
by guest on July 7, 2015Downloaded from
contracted using high potassium physiological salt solution (KPSS),
CBD-induced vasorelaxation was significantly inhibited (R
P,0.001, n¼5Figure 2D). Although incubation with L-NAME did
not significantly affect the concentration– response curve to CBD
(Figure 2B,Table 2), a trend for a reduction in the vasorelaxant effect
of CBD was seen. Therefore, in cultured endothelial cells, we tested
whether CBD affects eNOS activation and found that CBD
(10 mmol/L, 10 min) significantly increased eNOS phosphorylation at
ser1177 (P,0.05, n¼9, Figure 2F). Neither endothelium-denudation,
L-NAME, or KPSS contraction affected control vasorelaxant responses
(see Supplementary material online, Figure S2).
Antagonism of the CB
receptor using AM251 (100 nmol/L) signifi-
cantly inhibited CBD-induced vasorelaxation (R
P,0.001, n¼9,
Figure 3A,Table 2). To confirm this result, a second, structurally differ-
ent antagonist LY320135 was used, which also significantly reduced the
maximal response to CBD (CBD R
45 +3.5; CBD&LY R
30 +
5.4, P,0.05, Table 2). Antagonism of the CB
receptor using AM630
(100 nmol/L) had no effect on CBD-induced vasorelaxation (n¼8,
Figure 3C). Desensitization of TRP channels using capsaicin (10 mmol/
L) reduced CBD-induced vasorelaxation (P,0.0001, n¼7,
Figure 3B). Antagonism of the proposed CB
receptor using O-1918
(10 mmol/L, n¼7, Figure 3D) had no effect on the CBD-induced vasor-
elaxation. In the presence of the PPARgantagonist GW9662, neither
the immediate nor the time-dependent vasorelaxation was inhibited
(n¼5, representative raw trace shown in Figure 1B). Neither
AM251, LY320135, or capsaicin pre-treatment affected control vasor-
elaxant responses (see Supplementary material online, Figure S2).
In experiments to determine the location of the CB
AM251, and endothelial denudation were compared in combination
and individually against control CBD responses, obtained from adjacent
segments of artery from the same patients (n¼6, Figure 4A). AM251
alone, and AM251 plus denudation, resulted in a significant reduction
in the maximal response (R
Figure 4C). However, when looking at the entire concentration re-
sponse curve to CBD (AUC values), the combination of AM251 and
endothelial denudation had a more significant (P,0.01) reduction
than AM251 alone (P,0.05, Figure 4B).
Across the 37 patients tested, considerable variability of control
responses to CBD was observed among patients (the maximal re-
sponse to CBD ranged from 2 to 75% relaxation), so post hoc analysis
was carried out to establish any relationships between CBD responses
and patient characteristics (see Supplementary material online, Table S1
and Figures 3and 4). CBD responses were slightly reduced in males
compared with females (P¼0.0166), but were not affected by age,
BMI, or smoking status. Looking at concurrent diseases, CBD re-
sponses were reduced in patients with type-2 diabetes (P,0.0001),
Figure 1 CBD relaxes human mesenteric arteries. Typical trace data showing the acute (A) and time-dependent (B) vasorelaxant effects of CBD (also
in the presence of the PPARgamma antagonist GW9662) in the human mesenteric artery. (C) Mean (+SEM, n¼12) concentration-response curves to
CBD compared with vehicle controls carried out in adjacent segments of mesenteric artery from the same patient. The vasorelaxant response to
10 mmol/L bradykinin in the same patients is shown for comparison. (D) Mean time-dependent vasorelaxant response to a single concentration of
CBD (10 mmol/L) compared with vehicle controls carried out in adjacent segments of mesenteric artery (n¼6). R
and EC
values were compared
by paired Students t-test, *P,0.05, ****P,0.0001.
C.P. Stanley et al.Page 4 of 11
by guest on July 7, 2015Downloaded from
hypercholesterolemia (P¼0.0320), but not different in patients with
cancer, heart disease, or hypertension (Supplementary material online,
Figure S4). CBD responses were reduced in those taking statins
(P¼0.0042), hypoglycaemic medication (P,0.0001) and beta-blockers
(P¼0.0094), but not those taking ACE inhibitors or NSAIDs (Supple-
mentary material online, Figure S4).
To establish the intracellular mechanisms activated by CBD, human
aortic endothelial cells were treated for 10 min with increasing concen-
trations of CBD. This led to a significant reduction in phosphorylated
JNK (Figure 5B), NFkB(Figure 5C), p70s6 K (Figure 5G), and STAT5
(Figure 5I). CBD also significantly increased phosphorylated CREB
(only at 30 mM, Figure 5A), ERK1/2 (Figure 5E), and Akt (Figure 5F). In
the presence of the CB
receptor antagonist AM251 (100 nM) or the
TRPV1 antagonist capsazepine (1 mM), CBD no longer significantly in-
creased phosphorylated ERK1/2 (Figure 6A). The increase in phos-
phorylated Akt was only inhibited by AM251 (Figure 6B). The levels
of phosphorylated ERK1/2 (P¼0.0379, R ¼0.3639) and Akt (P¼
0.0343, R ¼0.3749), but none of the other intracellular signalling path-
ways, were positively correlated with the increase in phosphorylated
eNOS levels (Figure 6C). In the presence of AM251, the increase in
phosphorylated eNOS was no longer significant (Figure 6D).
As the CBD vasorelaxant responses were blunted in patients with
type-2 diabetes, we carried out RT-PCR in human aortic endothelial
cells (HAECs) to establish the effects of a high glucose (25 mM) or
high insulin (500 nM) environment on the expression of the relevant
target sites at the RNA level. Human astrocytes were used a positive
control for these target sites.
In HAECs, all targets (PPARaand g,
CB1R, CB2R, TRPV1, and CGRPR) were found to be present in control
conditions (see Figure 7). After 96 h in either a high insulin or high
glucose medium, the expression of CB2R appeared increased, and
the expression of TRPV1 and CGRPR appeared decreased (see
Figure 7).
4. Discussion
This is the first study to show that CBD-induces vasorelaxation in
human mesenteric arteries which is dependent on CB
and TRP recep-
tor activation, the endothelium, nitric oxide, and potassium channel
modulation. CBD-induced vasorelaxation is reduced in males, and in
patients with type-2 diabetes, hypercholesterolemia and in patients
taking statins, beta blockers and hypoglycaemic medication.
We found that CBD causes half-maximal vasorelaxation with a
in the mid-micromolar range. Similar findings have been re-
ported in the rat mesenteric artery, where CBD causes vasorelaxa-
tion with mid-micromolar potency, however, in the rat model CBD
caused near maximal vasorelaxation. This might suggest that the
efficacy of CBD is reduced in human vasculature. However, it should
be noted that the present studies were performed in older patients
with a variety of comorbidities and medications, while animal studies
are performed in same gender, young homogenous populations. As
we observed that some diseases and medications were associated
with lower responses to CBD, this might account for the apparent
reduced efficacy in humans. As no mechanistic studies with CBD in
animal tissue have yet been reported, we cannot compare the
mechanisms of action established in the present study with that
from animal tissue.
The endothelium mediates vasorelaxation of the CBD analogue
Abn-CBD, and this vasorelaxation is associated with activation of
the CB
receptor which is antagonized using O-1918.
We also
found that removal of the endothelium reduced responses to CBD
and that CBD vasorelaxant responses correlated with bradykinin re-
sponses, indicating an endothelial site of action for CBD. However, in
the presence of O-1918, CBD-induced vasorelaxation is unaltered,
suggesting that the endothelial component is not CB
that CBD responses tended to be reduced in the presence of
L-NAME. To explore this further, we found that CBD significantly in-
creased the phosphorylation of eNOS in human aortic endothelial
cells, suggesting that production of NO a least partially underlies
the endothelium-dependent vasorelaxant effect of CBD. The
present study also reports that CBD-induced vasorelaxation is
significantly inhibited in arteries contracted using high potassium
solution, as has been shown for the vascular response to many can-
nabinoids. This suggests a predominant mechanism of CBD-induced
vasorelaxation is activation of potassium channels and subsequent
hyperpolarization. Given the extent of inhibition caused by KPSS, it
is unlikely that potassium channel involvement is exclusive to the
Activation of CB
and CB
receptor has been implicated in
cannabinoid-induced vasorelaxation.
Since human vascular smooth
muscle and endothelial cells express these receptors,
30 35
and CBD
has been shown to bind to these receptors at low micromolar concen-
they were considered as potential mechanisms underpin-
ning CBD-induced vasorelaxation. Antagonism of the CB
receptor in
two separate experiments using AM251 (see Figures 3and 4) revealed
inhibition of CBD-induced vasorelaxation, suggesting CB
is a target for
CBD. A second structurally different antagonist, LY320135, was also
found to inhibit the vasorelaxant response to CBD, further implicating
receptor activation. Other authors have suggested that CBD may
Table 2 The maximal vasorelaxant responses and
potency of CBD in human mesenteric arteries
Vehicle CBD n
10.2 +3.5 39.2 +4.0 ****
24.98 +0.87 25.14 +0.21 12
Control CBD Intervention n
Minus endothelium R
51.6 +2.8 44.6 +3.8
25.84 +0.18 25.21 +0.18 **** 8
51.4 +4.9 39.1 +6.6
25.39 +0.26 25.24 +0.35 6
Indomethacin R
50.4 +4.0 55.2 +4.6
25.82 +0.26 25.26 +0.20 6
KPSS contracted R
49.7 +5.8 8.9+2.4 ***
25.45 +0.30 25.59 +0.73 5
AM251 R
53.9 +3.7 24.2 +4.9 ***
25.57 +0.19 25.53 +0.49 9
LY320135 R
45.0 +3.5 30.2 +5.4 *
25.83 +0.24 25.88 +0.54 6
AM630 R
58.7 +3.9 59.5 +5.5
25.56 +0.17 25.48 +0.23 8
47.7 +2.4 21.3 +3.9 ****
25.92 +0.15 25.85 +0.39 7
O-1918 R
51.8 +2.8 43.8 +3.9
25.68 +0.16 25.61 +0.26 7
Sigmoidal concentration-response curves to CBD were fitted using Prism and R
values were compared by Student’s t test (with Welch’s correction for groups
with unequal standard deviations).
CBD Induced vasorelaxation of human arteries Page 5 of 11
by guest on July 7, 2015Downloaded from
have indirect actions at CB
through inhibition of FAAH activity or
rather than direct activation. However, we have previously
shown that CBD is a more efficacious vasorelaxant of human mesen-
teric arteries that anandamide
and that the mechanisms of action
of CBD presented in the present study are different to those revealed
recently in our laboratory for the endocannabinoid 2-AG.
this, CBD has low affinity for CB
receptors so the possibility still exists
that some of the actions of CBD are through inhibition of endocanna-
binoid degradation. Antagonism of the CB
receptor using AM630 did
not inhibit CBD-induced vasorelaxation. This was unsurprising as CB
receptor activation is not commonly found to underpin the vasorelax-
ant effects of cannabinoids.
The CB
receptor is expressed in both human endothelial cells and
vascular smooth muscle cells.
In order to establish the location of
the CB
receptor mediated the vasorelaxant response to CBD, we
compared responses with CBD in arteries both denuded and treated
with AM251 to either intervention alone. Although the reduction in
the maximal response to CBD was similar in arteries treated with
AM251 alone as to both interventions, the entire responseto CBD (re-
presented by the AUC data) was more significantly reduced by the
combination of both interventions. We take this data to suggest that
CBD acts at CB
located on both the endothelium and smooth muscle.
activation has been shown to be coupled to the release of NO.
support of this, we found that in human endothelial cells, CBD
increased the phosphorylation of eNOS, the mRNA of CB1R was pre-
sent, and in the presence of AM251, the increase in eNOS phosphor-
ylation by CBD was no longer significant.
Plant-derived cannabinoids are good activators of the TRPV channel
and CBD induces cancer cell apoptosis
and anti-hyperalgaesic
responses to inflammatory pain
through activation of TRPV chan-
nels. In the present study, desensitization of TRP channels by exposure
to the TRPV1 agonist capsaicin inhibited CBD-induced vasorelaxation,
implicating TRP activation. In the rat mesenteric artery, vasorelaxation
to two chemically closely related cannabinoids, THC and cannabinol,
are also inhibited by capsaicin pre-treatment, acting via the release of
the vasoactive neuropeptide calcitonin gene-related peptide
Recent work showed that CGRP vasorelaxant responses
in human arteries are endothelium-independent,
suggesting the re-
sidual relaxation to CBD observed after endothelium-denudation is
probably the TRP component of this response. However, we also ob-
served that the increase in ERK caused by CBD in human endothelial
cells was inhibited by TRPV1 antagonism, indicating that TRP activation
on both the endothelium and smooth muscle cells could mediate some
of the effects of CBD.
Figure 2 Mechanisms of CBD-induced relaxation of human mesenteric arteries. Mean (+SEM) CBD-induced vasorelaxation of human mesenteric
arteries after removal of the endothelium (n¼8, A), in arteries incubated with L-NAME (300 mmol/L, n¼6, B), in the presence of the non-selective
COX inhibitor indomethacin (10 mmol/L, n¼6, D) or in arteries contracted using a high potassium (KPSS) Krebs (n¼5, E). (C) Maximal responses
to CBD correlated with the vasorelaxant response to the endothelium-dependent vasorelaxant bradykinin. (F) In cultured human aortic endothelial cells,
CBD (10 mmol/L, 10 min) increased eNOS phosphorylation at ser1177 (n¼9). Control responses to CBD and interventions were carried out in ad-
jacent segments of mesenteric artery from the same patient. R
and EC
values were compared by paired Students t-test, *P,0.05, **P,0.01,
***P,0.001, ****P,0.0001.
C.P. Stanley et al.Page 6 of 11
by guest on July 7, 2015Downloaded from
Figure 4 Location of the CB
receptor. Mean CBD-induced vasorelaxation in control arteries, endothelial denuded arteries, in arteries incubated with
the CB
antagonist AM251 or in arteries that are endothelial denuded and incubated with AM251 (A) and the corresponding R
(B) and AUC (C) values
within each patient (n¼6). Control responses to CBD and the three interventions were carried out in adjacent segments of mesenteric artery from the
same patient. Data were compared using one way analysis of variance (ANOVA) with Dunnett’s post hoc analysis comparing against the CBD control data.
*P,0.05, **P,0.01.
Figure 3 Target sites of action for CBD-induced relaxation of human mesenteric arteries. CBD-induced vasorelaxation of human mesenteric arteries
after 10 min incubation (pre-contraction) with the CB
antagonist AM251 (100 nmol/L, n¼9, A), the CB
antagonist AM630 (100 nmol/L, n¼8, C), the
proposed endothelial receptor (CB
) antagonist O-1918 (10 mmol/L, n¼7, D), or after desensitization of sensory nerves by 1 h pre-treatment with the
TRPV1 agonist capsaicin (10 mmol/L, n¼7, B). Control responses to CBD and interventions were carried out in adjacent segments of mesenteric artery
from the same patient. R
and EC
values were compared by paired Students t-test ,*P,0.05, **P,0.01, ***P,0.001, ****P,0.0001.
CBD Induced vasorelaxation of human arteries Page 7 of 11
by guest on July 7, 2015Downloaded from
In the rat aortae, CBD causes time-dependent vasorelaxation that
can be inhibited by PPARgantagonism.
In human small mesenteric
arteries, we found that CBD-induced vasorelaxation also gradually in-
creases with time, but this effect was not inhibited by PPARgantagon-
ism. However, we previously observed in rats that PPARgmediated
time-dependent vasorelaxant responses to cannabinoids were only
observed in conduit arteries such as the superior mesenteric artery
and aorta, but not in third-order mesenteric arteries.
Thus the
lack of PPARg-mediated vasorelaxation seen to CBD may be due to
the size of the arteries in the present study. An interesting observation
was that the vasorelaxant response to CBD was non-recoverable,
persisting up to 2 h post-administration. This is in contrast to our
previous observations with THC
where tone recovered. However,
the mechanisms of action (CB
, NO, and the endothelium) of CBD
reported in the present study are very different to that reported
for THC.
Figure 5 Signal transduction by CBD in human endothelial cells. Levels of phosphorylated CREB (A), JNK (B), NFkB(C), p38 (D), ERK/MAP kinase 1/2
(E), Akt (F), p70 S6 kinase (G), STAT3 (H), and STAT5A/B (I) were measured in human aortic endothelial cell lysates after 10 min treatment with in-
creasing concentrations of CBD using the Luminex
technology and normalized to total protein content. MFI, median fluorescent intensity. Data
are presented as mean +SEM (n¼6) and were analysed by ANOVA with Dunnett’s post-hoc analysis against the vehicle control response. *P,0.05,
**P,0.01, ***P,0.001, ****P,0.0001.
C.P. Stanley et al.Page 8 of 11
by guest on July 7, 2015Downloaded from
Human endothelial cell-based studies showed that CBD causes a
range of intracellular signalling pathwaysto be altered at concentrations
from 100 nM, but not in a classical concentration-dependent manner.
This non-classical concentration response, particularly for ERK and
Akt activation, may be a result of activation of multiple targets by
CBD. Indeed the ERK activation appeared to be inhibited by antagonists
of both CB
and TRPV1. Bell-shaped response curves to CBD are also
commonly observed.
The observed phosphorylation of ERK and
Akt is consistent with known CB
-mediated signal transduction, and
-mediated activation of ERK has been observed in human umbilical
vein endothelial cells.
Indeed, we found that CB
antagonism pre-
vented this increase in ERK. Cannabinoid activation of both MAPK
and Akt in the vasculature has also been suggested to be via non-CB
mechanisms such as CB
However, given our response to
CBD was not antagonized by O-1918, it is unlikely that CBD acts
through this site. Vasorelaxation to many compounds is mediated by
activation of ERK and Akt, thus the CBD-induced increased in both
ERK and Akt and therefore both may represent the intracellular signal-
ling mechanisms underpinning the vasorelaxant effects of CBD, as sug-
gested by the positive correlation with eNOS phosphorylation and the
inhibition of eNOS phosphorylation by AM251.
CBD also significantly decreased the level of phosphorylated JNK and
NFkB, key pro-inflammatory pathways, in human endothelial cells. This is
consistent with previous studies showing CBD can attenuate the increase
in JNK and NFkB caused by hepatic ischemia/reperfusion injury,
ic cardiomyopathy,
and hyperglycaemia.
Our data suggest that reduc-
tions in these inflammatory pathways in endothelial cells may underpin
some of the protective effects of CBD observed in the vasculature.
Previous studies have shown a decrease in the phosphorylation of
p70s6K, an mTOR substrate, in response to synthetic CB
or THC
in cancer cells linked to autophagy pathways. STAT5 is
also crucial in the regulation of cell fate, and its activation is key in angio-
The reduction in the levels of phosphorylated p70s6K and
STAT5 in human endothelial cells in response to CBD in the present
study may represent the intracellular signalling mechanisms underpin-
ning the anti-angiogenic effects of CBD reported by Solinas et al.
human umbilical vein endothelial cells.
Given the variability of the responses seen to CBD, post hoc analysis
of patient medical notes was undertaken. We found that CBD-induced
Figure 7 The effects of high insulin and glucose on the expression
of cannabinoid targets in HAECs. RT-PCR showing the presence of
PPARaand g,CB
, TRPV1, CGRP receptors, and a house-
keeping gene hypoxanthine-guanine phosphoribosyltransferase
(HPRT) in human aortic endothelial cells (HAECs) grown in control
conditions (first column) or a high insulin (500 nM, second column) or
high glucose (25 mM, third column) environment for 96 h. Human as-
trocytes (HA) are shown as a positive control for cannabinoid targets.
Figure 6 Signal transduction by CBD in human endothelial cells. Levels of phosphorylated ERK/MAP kinase 1/2 (A) and Akt (B) measured in human
aortic endothelial cell lysates after 10 min treatment with CBD in the presence of the CB
antagonist AM251 (100 nM) or the TRPV1 antagonist capza-
sepine (1 mM). (C) Correlation of levels of phosphorylated ERK1/2 and Akt with levels of phosphorylated eNOS in human aortic endothelial cell lysates
after 10 min treatment with CBD. MFI, median fluorescent intensity. (D) The effects of the CB
receptor antagonist AM251 on CBD-stimulated eNOS
phosphorylation. Data are presented as mean +SEM (n¼6) and were analysed by ANOVA with Sidak’s multiple comparison test of selected pairs.
**P,0.01, ***P,0.001.
CBD Induced vasorelaxation of human arteries Page 9 of 11
by guest on July 7, 2015Downloaded from
vasorelaxation was enhanced in females compared with males. The en-
hanced vasorelaxation observed in female patient arteries compared
with males may be due to protective effects of oestrogen on endothe-
lial function.
It has also been shown that CB
receptor expression was
increased in the leucocyte cells of females when compared with
CBD responses were also reduced in those with increased
cholesterol or diabetes. In rats fed high cholesterol diets, CB
expression is reduced.
Similarly, CB
expression is reduced (and as-
sociated vasorelaxant responses to anandamide) in obese rats.
test whether this might also be true in human aortic endothelial cells,
we carried out RT-PCR on the major targets for cannabinoid in control
condition and after prolonged exposure to a high-glucose or high-
insulin environment. We did not find a reduction in CB1R expression;
however, CB2R expression did appear to be up-regulated, which is in
agreement with numerous studies showing that CB
is up-regulated in
vasculature pathologies.
We did however also observe a decrease in
the expression of TRPV1 and CGRPR in response to both a high-
glucose or high-insulin medium, which is consistent with reports show-
ing that TRPV1 vasorelaxant responses and receptor coupling to nitric
oxide is disrupted in diabetes.
Interestingly, the TRPV1 receptor has a
cholesterol binding site which reduces its function.
Thus the blunted
CBD response in diabetic and hypercholesteraemia patients may be as
a result of reduced TRPV1 expression and/or function, which warrants
further investigation. Several medications (beta blockers, statins, and
oral hypoglycaemics) were also associated with reduced vasorelaxant
responses to CBD, but it is not yet clear whether this represents a
drug drug interaction, or whether it is a result of the pathology for
which the medication is being taken.
In conclusion, this study reports that CBD causes vasorelaxation of
the human mesenteric artery. This vasorelaxation is mediated through
, TRP channels, the endothelium and potassium channel activation.
CBD also causes time-dependent vasorelaxation of human mesenteric
arteries, but this was not due to PPARgactivation. The vasorelaxant
effects of CBD are reduced in patients with hypercholesterolemia
and type-2 diabetes, which may be a result of a reduced TRPV1 com-
ponent. In human endothelial cells, CBD causes alterations in the phos-
phorylation of many intracellular proteins that might explain the
vasorelaxant (eNOS, ERK, and Akt), anti-inflammatory (JNK and
NFkB) and anti-angiogenic effects of CBD (p70s6K and STAT5).
Supplementary material
Supplementary Material is available at Cardiovascular Research online.
This work was supported by the British Heart Foundation (FS/09/061).
Funding to pay the Open Access publication charges for this article was
provided by the British Heart Foundation.
Conflict of interest: none declared.
1. Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies.
Br J Pharmacol 2014;171:1361 –1378.
2. Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in
cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331 340.
3. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis
with high cannabidiol content is associated with fewer psychotic experiences. Schizophr
Res 2011;130:216 –221.
4. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant canna-
binoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Br J Pharmacol 2008;153:199 –215.
5. Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target
for cannabidiol? Br J Clin Pharmacol 2013;75:313 322.
6. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining
tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234 246.
7. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant can-
nabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci
8. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of
action. Rev Bras Psiquiatr 2008;30:271 –280.
9. Iuvone T, Esposito G, De Filippis D, Scuderi C, Ste ardo L. Cannabidiol: a promising drug
for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65–75.
10. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of
inflammation on oxidative stress. Free Radical Bio Med 2011;51:1054 1061.
11. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y,
Horvath B, Mukhopadhyay B, Becker L, Hasko G, Liaudet L, Wink DA, Veves A,
Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress,
fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
J Am Coll Cardiol 2010;56:2115 2125.
12. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR, Obrosova IG,
Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory
response and barrier disruption. Am J Physiol Heart Circ Physiol 2007;293:H610 H619.
13. Ruiz-Valdepenas L, Martinez-Orgado JA, Benito C, Millan A, Tolon RM, Romero J.
Cannabidiol red uces lipopolysac charide-indu ced vascular changes and inflammation
in the mouse brain: an intravital microscopy study. J Neuroinflammation 2011;8:5.
14. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai N-T, Caldwell RB, Liou GI. Neuropro-
tective and blood-retinal barrier-preserving effects of cannabidiol in experimental
diabetes. Am J Pathol 2006;168:235– 244.
15. Walsh SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol
in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when
given at reperfusion. Br J Pharmacol 2010;160:1234 1242.
16. Hayakawa K, Mishima K, Irie K, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N,
Katsurabayashi S, Takasaki K, Iwasaki K, Fujiwara M. Cannabidiol prevents a post-
ischemic injury progressively induced by cerebral ischemia via a high-mobility group
box1-inhibiting mechanism. Neuropharmacol 2008;55:1280 1286.
17. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K,
Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Repeated treatment with cannabidiol but
not Delta9-tetrahydroca nnabinol has a neuroprotec tive effect without the develop-
ment of tolerance. Neuropharmacol 2007;52:1079 1087.
18. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol
prevent s cerebral infarc tion vi a a seroto nergic 5-hydroxytry ptamin e1A receptor-
dependent mechanism. Stroke 2005;36:1077–1082.
19. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K,
Hasebe N, Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with cannabidiol
has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-
inhibiting mechanism. J Neurochem 2007;102:1488 1496.
20. JaraiZ,WagnerJA,VargaKR,LakeKD,ComptonDR,MartinBR,ZimmerAM,
Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoid-
induced mesenteric vasodilation through an endothelial site distinct from CB1 or
CB2 receptors. Proc Natl Acad Sci USA 1999;96:14136 14141.
21. Offerta
´ler L, Mo FM, Ba
Kunos G. Selective ligands and ce llular effectors of a G protein-co upled endothelial
cannabinoid receptor. Mol Pharmacol 2003;63:699 705.
22. O’Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA. Time-dependent vascular
actions of cannabidiol in the rat aorta. Eur J Pharmacol 2009;612:61 68.
23. Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O’Sullivan SE. Endocan-
nabinoids modulate human blood -brain barrier permeability in vitro. Br J Pharmacol
2015. doi:10.1111/bph.13106.
24. Spinsanti G, Zannolli R, Panti C, Ceccarelli I, Marsili L, Bachiocco V, Frati F, Aloisi AM.
Quantitative real-time PCR detection of TRPV1 –4 gene expression in human leuko-
cytes from healthy and hyposensitive subjects. Mol Pain 2008;4:51.
25. Reynders V, Loitsch S, Steinhauer C, Wagner T, Steinhilber D, Bargon J. Peroxisome
proliferator-activated receptor alpha (P PAR alpha) down-regulation in cystic fibrosis
lymphocytes. Resp Res 2006;7:104.
26. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L,
Maccarrone M. Anandamide suppresses proliferation and cytokine release from pri-
mary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010;5:e8688.
27. Luo D, Zhang YW, Peng WJ, Peng J, Chen QQ, Li D, Deng HW, Li YJ. Transient recep-
tor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived
calcitonin gene-related peptide. Regul Peptides 2008;150:66 72.
28. Dong YL, Fang L, Kondapaka S, Gangula PR, Wimalawansa SJ, Yallampalli C. Involve-
ment of calcitonin gene-related peptide in the modulation of human myometrial
contractility during pregnancy. J Clin Invest 1999;104:559 565.
29. Begg M, Mo FM, Offertaler L, Ba
´tkai S, Pacher P, Razdan RK, Lovinger DM, Kunos G. G
protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a
-dependent K
current. J Biol Chem 2003;278:46188 46194.
30. Fantozzi I, Zhang S, Platoshyn O, Remillar d CV, Cowling RT, Yuan JXJ. Hypoxia in-
creases AP-1 binding activity by enhancing capacitative Ca
entry in human pulmonary
artery endothelial cells. Am J Physiol 2003;285:L1233 L1245.
C.P. Stanley et al.Page 10 of 11
by guest on July 7, 2015Downloaded from
31. Wang J, Okamoto Y, Tsuboi K, Ueda N. The stimulatory effect of phosphatidylethano-
lamine on N-acylphosphatidylethanolamine-hydrolyzing phospholipase D
(NAPE-PLD). Neuropharmacol 2008;54:8 15.
32. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an en-
dogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 re-
ceptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible
vasomodulator? Biochem Biophys Res 1998;243:838 843.
33. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, Csiszar A,
TNF-alpha-induced huma n endothelial cell activation, transendothelial migration of
monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007;
34. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabin-
oid receptor agonists att enuate TNF-alpha-induced human vascular smooth muscle
cell proliferation and migration. Br J Pharmacol 2008;153:347 357.
35. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, Kunos G. Functional
CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000;346(Pt
3):835– 840.
36. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a trans-
fected cell line expressing a peripheral cannabinoid receptor (CB2): identification of
cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278:
989– 999.
37. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS,
Davis JB, Mechoulam R, Di Marzo V. Molecular targets for canna bidiol and its synthetic
analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic
hydrolysis of anandamide. Br J Pharmacol 2001;134:845 852.
38. Stanley C, Mannin g G, O’Sullivan S. Cannabinoid induced vasorelaxation of human
mesenteric arteries. Proceeding of the British Pharmacolgoical Scoiety Meeting 2010.
39. Stanl ey CP, O’Sulliva n SE. Cyclooxygenase metabolism me diates vasorelaxation to
2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res 2014;81:
74– 82.
40. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK,
Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of
anandamide in the vasculature of the rat kidney. J Clin Invest 1997;100:1538– 1546.
41. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di
Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP
channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:
1479– 1494.
42. Yamada T, Ueda T, Shibata Y, Ikegami Y, Saito M, Ishida Y, Ugawa S, Kohri K, Shimada S.
TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a po-
tential therapeutic target for bladder cancer. Urology 2010;76:509 e501 –507.
43. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Van illoid TRPV1 receptor
mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol,
in a rat model of acute inflammation. Br J Pharmacol 2004;143:247 250.
44. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. Thenon-psychoactive canna-
bis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflam-
matory and neuropathic pain. Eur J Pharmacol 2007;556:75 83.
45. Zygmunt PM, Andersson DA, Hogestatt ED. Delta 9-tetrahydrocannabinol and canna-
binol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid
receptor-independent mechanism. J Neurosci 2002;22:4720 4727.
46. Edvinsson L, Ahnstedt H, Larsen R, Sheykhzade M. Differential localization and
characterization of functional calcitonin gene-related peptide receptors in human sub-
cutaneous arteries. Acta Physiol 2014;210:811 822.
47. O’Sullivan SE, Kendall DA, Randall MD. Further characterization of the time-de pendent
vascular effects of D
tetrahydrocannabinol. J Pharmacol Exp Ther 2006;317:428 –438.
48. O’Sullivan SE, Kendall DA, Randall MD. The effects of Delta9-tetrahydrocannabinol in
rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.
Br J Pharmacol 2005;145:514 –526.
49. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ,
Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychotropic component
of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of
5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol
50. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like ef-
fects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psycho-
pharmacol 2008;199:223–230.
51. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 canna-
binoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
J Pharmacol Exp Ther 2007;321:930 937.
52. Mo FM, Offertaler L, Kunos G. Atypical cannabinoid stimulates endothelial cell migra-
tion via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol
53. Mukhopadh yay P, Rajesh M, Horva th B, Batkai S, Park O, Tanchian G, G ao RY,Pat el V,
Wink DA, Liaudet L, Hasko G, Mechoulam R, Pacher P. Can nabidiol protects against
hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and
response, oxidative/nitrative stress, and cell death. Free Rad Biol Med 2011;50:
1368– 1381.
54. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D’Alessandro A, Zolla L, Palmieri M.
Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in
pancreatic cancer cells. Cell Death Dis 2013;4:e664.
55. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A,
Cecconi F, Pandolfi PP, Gonzalez-Feria L, Iovanna JL, Guzman M, Boya P, Velasco G.
Cannabinoid action induces a utophagy-mediat ed cell death through stimulation o f
ER stress in human glioma cells. J Clin Invest 2009;119:1359 1372.
56. Yang X, Meyer K, Friedl A . STAT5 and prolactin participate in a positive autocrin e
feedback loop that promotes angiogenesis. J Biol Chem 2013;288:21184 21196.
57. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V,
Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Cannabidiol inhibits
angiogenesis by multiple mechanisms. Br J Pharmacol 2012;167:1218 1231.
58. Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular aging in women:
is estrogen the fountain of youth? Front Physiol 2012;3:165.
59. Onaivi ES, Chaudhuri G, Abaci AS, Parker M, Manier DH, Martin PR, Hubbard JR. Ex-
pression of cannabinoid receptors and their gene transcripts in human blood cells. Prog
Neuropsychopharmacol Biol Psychiatry 1999;23:1063–1077.
60. Lobato NS, Filgueira FP, Prakash R, Giachini FR, Ergul A, Carvalho MH, Webb RC,
Tostes RC, Fortes ZB. Reduced endo thelium-dependent relaxation to anandamide
in mesenteric arteries from young obese Zucker rats. PLoS One 2013;8:e63449.
61. Steffens S, Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders:
promises and controversies. Br J Pharmacol 2012;167:313–323.
62. Guarini G, Ohanyan VA, Kmetz JG, DelloStritto DJ, Thoppil RJ, Thodeti CK,
Meszaros JG, Damron DS, Bratz IN. Disruption of TRPV1-mediated coupling of
coronary blood flow to cardiac metabolism in diabetic mice: role of nitric oxide and
BK channels. Am J Physiol Heart Circ Physiol 2012;303:H216 H223.
63. Picazo-Jua
´rez G, Romero-Sua
´rez S, Nieto-Posadas A, Llorente I, Jara-Oseguera A,
Briggs M, McIntosh TJ, Simon SA, Ladro
´n-de-Guevara E, Islas LD, Rosenbaum T.
Identification of a binding motif in the S5 helix that confers cholesterol sensitivit y to
the TRPV1 ion channel. J Biol Chem. 2011;286:24966 24976.
CBD Induced vasorelaxation of human arteries Page 11 of 11
by guest on July 7, 2015Downloaded from
... In this review, we focus on papers published after Stanley et al. (Table 2) [14]. The relaxation induced by various cannabinoids might be dependent on the endothelium [22,[35][36][37][38][39][40][41][42] and/or receptors (e.g., CB 1 -Rs) [22,35,37,38,[40][41][42][43] ( Table 2). The potency of individual compounds depends on the vascular bed and species. ...
... In this review, we focus on papers published after Stanley et al. (Table 2) [14]. The relaxation induced by various cannabinoids might be dependent on the endothelium [22,[35][36][37][38][39][40][41][42] and/or receptors (e.g., CB 1 -Rs) [22,35,37,38,[40][41][42][43] ( Table 2). The potency of individual compounds depends on the vascular bed and species. ...
... Similarly, CBD-induced hPA relaxation is also NO-independent [22]. In systemic vessels, NO appears to be involved in the AEA- [38] and CBD-induced [37] relaxation of human mesenteric arteries (hMAs) ( Table 2). Similarly, NAGly- [39], CBD- [46], JHW-133-, and APCA-induced [41] relaxation in rMAs was shown to be attenuated by L-NAME administration. ...
Full-text available
Currently, no treatment can completely cure pulmonary hypertension (PH), which can lead to right ventricular failure and, consequently, death. Therefore, searching for new therapies remains important. Increased resistance in pulmonary circulation is mainly caused by the excessive contraction and proliferation of small pulmonary arteries. Cannabinoids, a group of lipophilic compounds that all interact with cannabinoid receptors, exert a pulmonary vasodilatory effect through several different mechanisms, including mechanisms that depend on vascular endothelium and/or receptor-based mechanisms, and may also have anti-proliferative and anti-inflammatory properties. The vasodilatory effect is important in regulating pulmonary resistance, which can improve patients' quality of life. Moreover, experimental studies on the effects of cannabidiol (plant-derived, non-psychoactive cannabinoid) in animal PH models have shown that cannabidiol reduces right ventricular systolic pressure and excessive remodelling and decreases pulmonary vascular hypertrophy and pulmonary vascular resistance. Due to the potentially beneficial effects of cannabinoids on pulmonary circulation and PH, in this work, we review whether cannabinoids can be used as an adjunctive therapy for PH. However, clinical trials are still needed to recommend the use of cannabinoids in the treatment of PH.
... The vasodilatory effect of CBD is the most consistent effect of this compound in the cardiovascular system and has been demonstrated on isolated human and animal vessels under both physiological [10,[16][17][18][19] and pathological [10,20,21] conditions. CBD-mediated relaxation has been demonstrated in human mesenteric [19] and pulmonary [10] arteries and in rat aortas [17] and femoral [18] and mesenteric arteries under normotensive and hypertensive conditions [10]. ...
... The vasodilatory effect of CBD is the most consistent effect of this compound in the cardiovascular system and has been demonstrated on isolated human and animal vessels under both physiological [10,[16][17][18][19] and pathological [10,20,21] conditions. CBD-mediated relaxation has been demonstrated in human mesenteric [19] and pulmonary [10] arteries and in rat aortas [17] and femoral [18] and mesenteric arteries under normotensive and hypertensive conditions [10]. The vasodilatory effects of CBD in the human mesenteric artery were dependent on the endothelium, the potassium channel, the transient receptor potential vanilloid 1 (TRPV1), cyclooxygenase (COX) derivatives, NO and the cannabinoid CB1 receptors; those in the rat aorta depended on peroxisome proliferator-activated receptors (PPARs), calcium channel inhibition and superoxide dismutase (SOD) [17,19]. ...
... CBD-mediated relaxation has been demonstrated in human mesenteric [19] and pulmonary [10] arteries and in rat aortas [17] and femoral [18] and mesenteric arteries under normotensive and hypertensive conditions [10]. The vasodilatory effects of CBD in the human mesenteric artery were dependent on the endothelium, the potassium channel, the transient receptor potential vanilloid 1 (TRPV1), cyclooxygenase (COX) derivatives, NO and the cannabinoid CB1 receptors; those in the rat aorta depended on peroxisome proliferator-activated receptors (PPARs), calcium channel inhibition and superoxide dismutase (SOD) [17,19]. The protective role of CB1 receptors in the vasodilatory effect of CBD in mesenteric arteries has been indicated only in hypertensive rats and not in normotensive control rats [10]. ...
Full-text available
Our study aimed to examine the endothelium (vascular)-protecting effects of chronic cannabidiol (CBD) administration (10 mg/kg once daily for 2 weeks) in aortas and small mesenteric (G3) arteries isolated from deoxycorticosterone-induced hypertensive (DOCA-salt) rats and spontaneously hypertensive rats (SHR). CBD reduced hypertrophy and improved the endothelium-dependent vasodilation in response to acetylcholine in the aortas and G3 of DOCA-salt rats and SHR. The enhancement of vasorelaxation was prevented by the inhibition of nitric oxide (NO) with L-NAME and/or the inhibition of cyclooxygenase (COX) with indomethacin in the aortas and G3 of DOCA-salt and SHR, respectively. The mechanism of the CBD-mediated improvement of endothelial function in hypertensive vessels depends on the vessel diameter and may be associated with its NO-, the intermediate-conductance calcium-activated potassium channel- or NO-, COX-, the intermediate and the small-conductance calcium-activated potassium channels-dependent effect in aortas and G3, respectively. CBD increased the vascular expression of the cannabinoid CB1 and CB2 receptors and aortic levels of endocannabinoids with vasorelaxant properties e.g., anandamide, 2-arachidonoylglycerol and palmitoyl ethanolamide in aortas of DOCA-salt and/or SHR. In conclusion, CBD treatment has vasoprotective effects in hypertensive rats, in a vessel-size- and hypertension-model-independent manner, at least partly via inducing local vascular changes in the endocannabinoid system.
... These disparate findings may reflect differences in cannabinoids and the models used, mode of administration, or effects on cannabinoid versus other receptors in the periphery and central nervous system. Our finding that CBG lowers blood pressure is consistent with reports that: synthetic cannabinoids including Δ 9 -THC may decrease blood pressure (Jones, 2002); cannabis users have increased risk of orthostatic hypotension (Mathew et al., 1992); CBD causes vasorelaxation in human mesenteric arteries (Stanley et al., 2015) and lowers blood pressure in hypertensive rats (Baranowska-Kuczko et al., 2020); and the sympathetic nervous appears to play a role in the cardiovascular depression effects of endocannabinoids (Niederhoffer et al., 2003;Dean, 2011). Despite this literature for other cannabinoids, very little is known about adverse effects or medication interactions for CBG, including potential effects on the cardiovascular system. ...
Full-text available
Cannabigerol is a cannabinoid compound synthesized by Cannabis sativa, which in its acid form acts as the substrate for both Δ9-tetraydrocannabinol and cannabidiol formation. Given its lack of psychoactive effects, emerging research has focused on cannabigerol as a potential therapeutic for health conditions including algesia, epilepsy, anxiety, and cancer. While cannabigerol can bind to classical cannabinoid receptors, it is also an agonist at α2-adrenoreceptors (α2AR) which, when activated, inhibit presynaptic norepinephrine release. This raises the possibility that cannabigerol could activate α2AR to reduce norepinephrine release to cardiovascular end organs to lower blood pressure. Despite this possibility, there are no reports examining cannabigerol cardiovascular effects. In this study, we tested the hypothesis that acute cannabigerol administration lowers blood pressure. Blood pressure was assessed via radiotelemetry at baseline and following intraperitoneal injection of cannabigerol (3.3 and 10 mg/kg) or vehicle administered in a randomized crossover design in male C57BL/6J mice. Acute cannabigerol significantly lowered mean blood pressure (−28 ± 2 mmHg with 10 mg/kg versus −12 ± 5 mmHg vehicle, respectively; p = 0.018), with no apparent dose responsiveness (−22 ± 2 mmHg with 3.3 mg/kg). The depressor effect of cannabigerol was lower in magnitude than the α2AR agonist guanfacine and was prevented by pretreatment with the α2AR antagonist atipamezole. These findings suggest that acute cannabigerol lowers blood pressure in phenotypically normal mice likely via an α2AR mechanism, which may be an important consideration for therapeutic cannabigerol administration.
... It is also believed that CBD could increase the human mesenteric artery vasorelaxation. Interestingly, CBD can decrease NF-κB and phosphorylated c-Jun N-terminal kinases (JNK); thus, preventing the phosphorylation of eNOS (Stanley et al. 2015). In a diabetic model of cardiac dysfunction, CBD treatment has resulted in cardiac function improvement through inhibition of NF-κB leading to decreased VCAM-1, ICAM-1, and TNF-α expressions as well as decreasing other agents involved in oxidative stress (Rajesh et al. 2010). ...
Full-text available
Background Among pathways involved in the pathogenesis of coronavirus disease 2019 (COVID-19), impaired endothelial cell (EC) function and angiogenesis have been discussed less frequently than others such as cytokine storm. These two do play parts in the development of various clinical manifestations of COVID-19 including acute respiratory distress syndrome (ARDS) and the hyper-coagulation state. Methods This narrative review attempts to gather recent data on the possible potential of cannabidiol in the treatment of COVID-19 with an eye on angiogenesis and endothelial dysfunction. Keywords including cannabidiol AND angiogenesis OR endothelial cell as well as coronavirus disease 2019 OR COVID-19 AND angiogenesis OR endothelial dysfunction were searched among the databases of PubMed and Scopus. Results Cannabidiol (CBD), as a therapeutic phytocannabinoid, has been approved by the Food and Drug Administration (FDA) for two types of seizures. Due to the potent anti-inflammatory properties of CBD, this compound has been suggested as a candidate treatment for COVID-19 in the literature. Although its potential effect on ECs dysfunction and pathologic angiogenesis in COVID-19 has been overlooked, other than cytokines like interleukin 1β (IL-β), IL-6, IL-8, and tumour necrosis factor α (TNFα) that are common in inflammation and angiogenesis, CBD could affect other important factors related to ECs function and angiogenesis. Data shows that CBD could decrease pathologic angiogenesis via decreasing ECs proliferation, migration, and tube formation. These activities are achieved through the suppression of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), urokinase plasminogen activator (uPA), matrix metalloproteinase 2 (MMP-2), MMP-9, intracellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). Moreover, in an animal model, ARDS and sepsis responded well to CBD treatment. Conclusion Altogether and considering the current use of CBD in the clinic, the conduction of further studies on CBD administration for patients with COVID-19 seems to be useful.
... Both claims are likely erroneous. CBD in fact does bind to CB1R receptors at high doses [192][193][194][195][196] which can presumably be achieved under high level dosing such as may commonly be seen under cannabis-legal paradigms, and CBD has mental and genotoxic effects which can be reversed by application of canonical CB1R antagonists [96]. ...
Introduction Breast cancer (BC) is the commonest human cancer and its incidence (BCI) is rising worldwide. Whilst both tobacco and alcohol have been linked to BCI genotoxic cannabinoids have not been investigated. Methods Age-adjusted state-based BC incidence (BCI) 2003-2017 was taken from the Surveillance Epidemiology and End Results database of the Centers for Disease Control (CDC). Drug use from the National Survey of Drug Use and Health, response rate 74.1%. Median age, median household income and ethnicity were from US census. Inverse probability weighted (ipw) multivariable regression conducted in R. Results In bivariate analysis BCI was shown to be significantly linked with rising cannabis exposure (β-est.=3.93 (95%C.I. 2.99, 4.87), P=1.10x10-15). At 8-years lag cigarettes: cannabis (β-est.=2660 (2150.4, 3169.3), P=4.60x10-22) and cannabis: alcoholism (β-est.=7010 (5461.6, 8558.4), P=1.80x10-17) were significant in ipw-panel regression. Terms including cannabidiol (β-est.=16.16 (0.39, 31.93), P=0.446) and cannabigerol (β-est.=6.23 (2.06, 10.39), P=0.0034) were significant in spatiotemporal models lagged 1:2 years respectively. Cannabis-liberal paradigms had higher BCI (67.50±0.26 v. 65.19±0.21/100,000 (mean±S.E.M.), P=1.87x10-11; β-est.= 2.31 (1.65, 2.96), P = 9.09x10-12). 55/58 e-Values >1.25 and 13/58 >100. Abortion was independently and causally significant in space-time models. Conclusion Data show that exposure to cannabis and the cannabinoids THC, cannabidiol, cannabigerol, and alcoholism fulfill quantitative causal criteria for BCI across space and time. Findings are robust to adjustment for age and several known sociodemographic, socioeconomic and hormonal risk factors, and establish cannabinoids as an additional risk factor class for breast carcinogenesis. BCI is higher under cannabis-liberal legal paradigms.
... Cannabinoids generally have vasodilatory reflex properties if they act through the CB1 receptor [186,187]. The response is complex and may consist of three phases with vagal-mediated hypotension (Phase I), followed by a compensatory increase in blood pressure (Phase II) to culminate in the prolonged hypotensive effect (Phase III) [188]. ...
Full-text available
Increased usage of recreational and medically indicated cannabinoid compounds has been an undeniable reality for anesthesiologists in recent years. These compounds’ complicated pharmacology, composition, and biological effects result in challenging issues for anesthesiologists during different phases of perioperative care. Here, we review the existing formulation of cannabinoids and their biological activity to put them into the context of the anesthesia plan execution. Perioperative considerations should include a way to gauge the patient’s intake of cannabinoids, the ability to gain consent properly, and vigilance to the increased risk of pulmonary and airway problems. Intraoperative management in individuals with cannabinoid use is complicated by the effects cannabinoids have on general anesthetics and depth of anesthesia monitoring while simultaneously increasing the potential occurrence of intraoperative hemodynamic instability. Postoperative planning should involve higher vigilance to the risk of postoperative strokes and acute coronary syndromes. However, most of the data are not up to date, rending definite conclusions on the importance of perioperative cannabinoid intake on anesthesia management difficult.
... CBD inhibits MMP 2, MMP 9, and tissue inhibitor of metalloproteinase 1, which results in the suppression of cell motility and the invasion of endothelial cells; also, CBD inhibits urokinase-type plasminogen activator (uPA) and serpin E1/plasminogen activator inhibitor 1, which are involved in the degradation of the extracellular matrix and contribute to cancer cell invasiveness. Moreover, CBD downregulates HIF1α in U87 cells, which suggests the suppression of cell survival, motility, and angiogenesis [256]; endothelin 1, PDGF-A [257]; and the reduction of STAT5-induced vasorelaxation [256,258]. In addition, the antimetastatic action of CB receptor agonists have been shown on SW480 cell lines. ...
Full-text available
Despite the multiple preventive measures and treatment options, colorectal cancer holds a significant place in the world’s disease and mortality rates. The development of novel therapy is in critical need, and based on recent experimental data, cannabinoids could become excellent candidates. This review covered known experimental studies regarding the effects of cannabinoids on intestinal inflammation and colorectal cancer. In our opinion, because colorectal cancer is a heterogeneous disease with different genomic landscapes, the choice of cannabinoids for tumor prevention and treatment depends on the type of the disease, its etiology, driver mutations, and the expression levels of cannabinoid receptors. In this review, we describe the molecular changes of the endocannabinoid system in the pathologies of the large intestine, focusing on inflammation and cancer.
Cannabidiol (CBD), as a major phytocannabinoid of Cannabis sativa, has emerged as a promising natural compound in the treatment of diseases. Its diverse pharmacological effects with limited side effects have promoted researchers to pursue new therapeutic applications. It has little affinity for classical cannabinoid receptors (CB1 and CB2). Considering this and its diverse pharmacological effects, it is logical to set up studies for finding its putative potential targets other than CB1 and CB2. A class of ion channels, namely transient potential channels (TRP), has been identified during two recent decades. More than 30 members of this family have been studied, so far. They mediate diverse physiological functions and are associated with various pathological conditions. Some have been recognized as key targets for natural compounds such as capsaicin, menthol, and CBD. Studies show that CBD has agonistic effects for TRPV1-4 and TRPA1 channels with antagonistic effects on the TRPM8 channel. In this article, we reviewed the recent findings considering the interaction of CBD with these channels. The review indicated that TRP channels mediate, at least in part, the effects of CBD on seizure, inflammation, cancer, pain, acne, and vasorelaxation. This highlights the role of TRP channels in CBD-mediated effects, and binding to these channels may justify part of its paradoxical effects in comparison to classical phytocannabinoids.
Full-text available
Background Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological and psychological responses to aerobic exercise to determine its practical utility within the sporting context. Methods On two occasions, nine endurance-trained males (mean ± SD V̇O 2max : 57.4 ± 4.0 mL·min ⁻¹ ·kg ⁻¹ ) ran for 60 min at a fixed intensity (70% V̇O 2max ) (RUN 1) before completing an incremental run to exhaustion (RUN 2). Participants received CBD (300 mg; oral) or placebo 1.5 h before exercise in a randomised, double-blind design. Respiratory gases (V̇O 2 ), respiratory exchange ratio (RER), heart rate (HR), blood glucose (BG) and lactate (BL) concentrations, and ratings of perceived exertion (RPE) and pleasure–displeasure were measured at three timepoints (T1–3) during RUN 1. V̇O 2max , RER max , HR max and time to exhaustion (TTE) were recorded during RUN 2. Venous blood was drawn at Baseline, Pre- and Post-RUN 1, Post-RUN 2 and 1 h Post-RUN 2. Data were synthesised using Cohen’s d z effect sizes and 85% confidence intervals (CIs). Effects were considered worthy of further investigation if the 85% CI included ± 0.5 but not zero. Results CBD appeared to increase V̇O 2 (T2: + 38 ± 48 mL·min ⁻¹ , d z : 0.25–1.35), ratings of pleasure (T1: + 0.7 ± 0.9, d z : 0.22–1.32; T2: + 0.8 ± 1.1, d z : 0.17–1.25) and BL (T2: + 3.3 ± 6.4 mmol·L ⁻¹ , d z : > 0.00–1.03) during RUN 1 compared to placebo. No differences in HR, RPE, BG or RER were observed between treatments. CBD appeared to increase V̇O 2max (+ 119 ± 206 mL·min ⁻¹ , d z : 0.06–1.10) and RER max (+ 0.04 ± 0.05 d z : 0.24–1.34) during RUN 2 compared to placebo. No differences in TTE or HR max were observed between treatments. Exercise increased serum interleukin (IL)-6, IL-1β, tumour necrosis factor-α, lipopolysaccharide and myoglobin concentrations (i.e. Baseline vs. Post-RUN 1, Post-RUN 2 and/or 1-h Post-RUN 2, p ’s < 0.05). However, the changes were small, making it difficult to reliably evaluate the effect of CBD, where an effect appeared to be present. Plasma concentrations of the endogenous cannabinoid, anandamide (AEA), increased Post-RUN 1 and Post-RUN 2, relative to Baseline and Pre-RUN 1 ( p ’s < 0.05). CBD appeared to reduce AEA concentrations Post-RUN 2, compared to placebo (− 0.95 ± 0.64 pmol·mL ⁻¹ , d z : − 2.19, − 0.79). Conclusion CBD appears to alter some key physiological and psychological responses to aerobic exercise without impairing performance. Larger studies are required to confirm and better understand these preliminary findings. Trial Registration This investigation was approved by the Sydney Local Health District’s Human Research Ethics Committee (2020/ETH00226) and registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12620000941965).
Full-text available
The commercialization of products with cannabidiol (CBD) has undergone a significant increase. These products can be presented in different forms such as baked goods, gummies or beverages (such as kombucha, beer or teas, among others) using wide concentrations ranges. The use of CBD in edibles favors its consumption, for medicinal users, during the work week, avoid its possible social stigma and facilitates its transport. These products can be purchased on store shelves and online. There is a large number of specialized studies, in which the possible advantages of CBD consumption are described in the preclinical and clinical trials. it is also necessary to recognize the existence of other works revealing that the excessive consumption of CBD could have some repercussions on health. in this review, it is analyzed the composition and properties of Cannabis sativa L., the health benefits of cannabinoids (focusing on CBD), its consumption, its possible toxicological effects, a brief exposition of the extraction process, and a collection of different products that contain CBD in its composition.
Full-text available
Background and purpose: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects. We therefore explored the role of endocannabinoids in modulating blood-brain barrier (BBB) permeability in normal conditions and in an ischaemia/reperfusion model. Experimental approach: Human brain microvascular endothelial cell and astrocyte co-cultures modelled the BBB. Ischaemia was modelled by oxygen-glucose deprivation (OGD) and permeability was measured by transepithelial electrical resistance. Endocannabinoids or endocannabinoid-like compounds were assessed for their ability to modulate baseline permeability or OGD-induced hyperpermeability. Target sites of action were investigated using receptor antagonists and subsequently identified with real-time PCR. Key results: Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance). This was mediated by cannabinoid CB2 receptors, transient receptor potential vanilloid 1 (TRPV1) channels, calcitonin gene-regulated peptide (CGRP) receptor (anandamide only) and PPARα (OEA only). Application of OEA, palmitoylethanolamide (both PPARα mediated) or virodhamine (all 10 μM) decreased the OGD-induced increase in permeability during reperfusion. 2-Arachidonoyl glycerol, noladin ether and oleamide did not affect BBB permeability in normal or OGD conditions. N-arachidonoyl-dopamine increased permeability through a cytotoxic mechanism. PPARα and γ, CB1 receptors, TRPV1 channels and CGRP receptors were expressed in both cell types, but mRNA for CB2 receptors was only present in astrocytes. Conclusion and implication: The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.
Full-text available
The vasorelaxant effect of 2-arachidonylglycerol (2-AG) has been well characterised in animals. 2-AG is present in human vascular cells and is up-regulated in cardiovascular pathophysiology. However, the acute vascular actions of 2-AG have not been explored in humans. Mesenteric arteries were obtained from patients receiving colorectal surgery and mounted on a myograph. Arteries were contracted and 2-AG concentration-response curves were carried out. Mechanisms of action were characterised pharmacologically. Post-hoc analysis was carried out to assess the effects of cardiovascular disease/risk factors on 2-AG responses. 2-AG caused vasorelaxation of human mesenteric arteries, independent of cannabinoid receptor or transient receptor potential vanilloid-1 activation, the endothelium, nitric oxide or metabolism via monoacyglycerol lipase or fatty acid amide hydrolase. 2-AG-induced vasorelaxation was reduced in the presence of indomethacin and flurbiprofen, suggesting a role for cyclooxygenase metabolism 2-AG. Responses to 2-AG were also reduced in the presence of Cay10441, L-161982 and potentiated in the presence of AH6809, suggesting that metabolism of 2-AG produces both vasorelaxant and vasoconstrictor prostanoids. Finally, 2-AG-induced vasorelaxation was dependent on potassium efflux and the presence of extracellular calcium. We have shown for the first time that 2-AG causes vasorelaxation of human mesenteric arteries. Vasorelaxation is dependent on COX metabolism, activation of prostanoid receptors (EP4 & IP) and ion channel modulation. 2-AG responses are blunted in patients with cardiovascular risk factors.
Full-text available
The anti-tumoral effects of cannabinoids have been described in different tumor systems, including pancreatic adenocarcinoma, but their mechanism of action remains unclear. We used cannabinoids specific for the CB1 (ACPA) and CB2 (GW) receptors and metabolomic analyses to unravel the potential pathways mediating cannabinoid-dependent inhibition of pancreatic cancer cell growth. Panc1 cells treated with cannabinoids show elevated AMPK activation induced by a ROS-dependent increase of AMP/ATP ratio. ROS promote nuclear translocation of GAPDH, which is further amplified by AMPK, thereby attenuating glycolysis. Furthermore, ROS determine the accumulation of NADH, suggestive of a blockage in the respiratory chain, which in turn inhibits the Krebs cycle. Concomitantly, inhibition of Akt/c-Myc pathway leads to decreased activity of both the pyruvate kinase isoform M2 (PKM2), further downregulating glycolysis, and glutamine uptake. Altogether, these alterations of pancreatic cancer cell metabolism mediated by cannabinoids result in a strong induction of autophagy and in the inhibition of cell growth.
Full-text available
We have shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal role in angiogenesis induced by the FGF2/STAT5 signaling cascade. To delineate the signaling pathway downstream of STAT5 in the human system, where proliferin does not exist, we expressed constitutively active (CA) or dominant-negative (DN) mutant STAT5A in hCMEC/D3 human brain endothelial cells. We found that conditioned medium from CA-STAT5A- but not from DN-STAT5A-overexpressing endothelial cells (EC) is sufficient to induce EC migration and tube formation but not proliferation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors. We identified prolactin (PRL) as a candidate autocrine factor. CA-STAT5A expression stimulates PRL production at the RNA and protein level, and STAT5A binds to the PRL promoter region, suggesting direct transcriptional regulation. Medium conditioned by CA-STAT5A-overexpressing EC induces phosphorylation of the PRL receptor and activates MAPK. Knockdown of PRL expression by shRNA or blocking of PRL activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC. The addition of recombinant PRL restores this activity. STAT5A-induced PRL in the conditioned medium can activate STAT5, STAT1, and to a lesser extent STAT3 in hCMEC/D3 cells, suggesting the existence of a positive feedback loop between STAT5 and PRL that promotes angiogenesis. Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A, and VEGF induction depends on PRL expression. These observations demonstrate a STAT5/PRL/VEGF signaling cascade in human brain EC and implicate PRL and VEGF as autocrine regulators of EC migration, invasion, and tube formation. Background: Active STAT5 promotes angiogenesis. Results: In human brain endothelial cells, active STAT5 promotes the secretion of prolactin, which stimulates endothelial cell migration and tube formation. Prolactin also induces the secretion of VEGF and activates STAT5. Conclusion: Prolactin and STAT5 are engaged in a positive feedback loop that stimulates angiogenesis. Significance: Prolactin may be important in pathologic angiogenesis.
Full-text available
Impaired vascular function, manifested by an altered ability of the endothelium to release endothelium-derived relaxing factors and endothelium-derived contracting factors, is consistently reported in obesity. Considering that the endothelium plays a major role in the relaxant response to the cannabinoid agonist anandamide, the present study tested the hypothesis that vascular relaxation to anandamide is decreased in obese rats. Mechanisms contributing to decreased anandamide-induced vasodilation were determined. Resistance mesenteric arteries from young obese Zucker rats (OZRs) and their lean counterparts (LZRs) were used. Vascular reactivity was evaluated in a myograph for isometric tension recording. Protein expression and localization were analyzed by Western blotting and immunofluorescence, respectively. Vasorelaxation to anandamide, acetylcholine, and sodium nitroprusside, as well as to CB1, CB2, and TRPV1 agonists was decreased in endothelium-intact mesenteric arteries from OZRs. Incubation with an AMP-dependent protein kinase (AMPK) activator or a fatty acid amide hydrolase inhibitor restored anandamide-induced vascular relaxation in OZRs. CB1 and CB2 receptors protein expression was decreased in arteries from OZRs. Incubation of mesenteric arteries with anandamide evoked endothelial nitric oxide synthase (eNOS), AMPK and acetyl CoA carboxylase phosphorylation in LZRs, whereas it decreased phosphorylation of these proteins in OZRs. In conclusion, obesity decreases anandamide-induced relaxation in resistance arteries. Decreased cannabinoid receptors expression, increased anandamide degradation, decreased AMPK/eNOS activity as well as impairment of the response mediated by TRPV1 activation seem to contribute to reduce responses to cannabinoid agonists in obesity.
Delta(9)-tetrahydrocannabinol binds cannabinoid (CB(1) and CB(2)) receptors, which are activated by endogenous compounds (endocannabinoids) and are involved in a wide range of physiopathological processes (e.g. modulation of neurotransmitter release, regulation of pain perception, and of cardiovascular, gastrointestinal and liver functions). The well-known psychotropic effects of Delta(9)-tetra hydrocannabinol, which are mediated by activation of brain CB(1) receptors, have greatly limited its clinical use. However, the plant Cannabis contains many cannabinoids with weak or no psychoactivity that, therapeutically, might be more promising than Delta(9)-tetra hydrocannabinol. Here, we provide an overview of the recent pharmacological advances, novel mechanisms of action, and potential therapeutic applications of such non-psychotropic plant-derived cannabinoids. Special emphasis is given to cannabidiol, the possible applications of which have recently emerged in inflammation, diabetes, cancer, affective and neurodegenerative diseases, and to Delta(9)-tetrahydrocannabivarin, a novel CB(1) antagonist which exerts potentially useful actions in the treatment of epilepsy and obesity.
Calcitonin gene-related peptide (CGRP) and its receptor are widely distributed within the circulation and the mechanism behind its vasodilation not only differs from one animal species to another but is also dependent on the type and size of vessel. The present study examines the nature of CGRP-induced vasodilation, characteristics of the CGRP receptor antagonist telcagepant and localization of the key components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) of the CGRP receptor in human subcutaneous arteries. CGRP-induced vasodilation and receptor localization in human subcutaneous arteries were studied by wire myograph in presence and absence of the CGRP receptor antagonist telcagepant and immunohistochemistry, respectively. At concentrations of 1, 3, 5, 10 and 30 nM, telcagepant had a competitive antagonist-like behavior characterized by a parallel rightward shift in the log CGRP concentration-tension/calcium curve with no depression of the maximal relaxation. CGRP-induced vasodilation was not affected by mechanical removal of the endothelium or addition of L-NG-Nitroarginine Methyl Ester and indomethacin, antagonists for synthesis of nitric oxide and prostaglandins, respectively. CLR and RAMP1 were localized in the vascular smooth muscle and endothelial cells. The present results indicate that CGRP exerts its vasodilatory effect in human subcutaneous arteries by binding to its receptors located on the smooth muscle cells, and is suggested to be endothelium-independent. In conclusion, these results underline the dynamic distribution of CGRP receptor components in human circulation reflecting the important role of CGRP in fine tuning of the blood flow in resistance arteries. This article is protected by copyright. All rights reserved.
Unlabelled: Application of cannabinoids and endocannabinoids to perfused vascular beds or individual isolated arteries results in changes in vascular resistance. In most cases, the result is vasorelaxation, although vasoconstrictor responses are also observed. Cannabinoids also modulate the actions of vasoactive compounds including acetylcholine, methoxamine, angiotensin II and U46619 (thromboxane mimetic). Numerous mechanisms of action have been proposed including receptor activation, potassium channel activation, calcium channel inhibition and the production of vasoactive mediators such as calcitonin gene-related peptide, prostanoids, NO, endothelial-derived hyperpolarizing factor and hydrogen peroxide. The purpose of this review is to examine the evidence for the range of receptors now known to be activated by cannabinoids. Direct activation by cannabinoids of CB1 , CBe , TRPV1 (and potentially other TRP channels) and PPARs in the vasculature has been observed. A potential role for CB2, GPR55 and 5-HT1 A has also been identified in some studies. Indirectly, activation of prostanoid receptors (TP, IP, EP1 and EP4 ) and the CGRP receptor is involved in the vascular responses to cannabinoids. The majority of this evidence has been obtained through animal research, but recent work has confirmed some of these targets in human arteries. Vascular responses to cannabinoids are enhanced in hypertension and cirrhosis, but are reduced in obesity and diabetes, both due to changes in the target sites of action. Much further work is required to establish the extent of vascular actions of cannabinoids and the application of this research in physiological and pathophysiological situations. Linked articles: This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit
(−)-Cannabidiol (CBD) is a non-psychotropic component of Cannabis with possible therapeutic use as an anti-inflammatory drug. Little is known on the possible molecular targets of this compound. We investigated whether CBD and some of its derivatives interact with vanilloid receptor type 1 (VR1), the receptor for capsaicin, or with proteins that inactivate the endogenous cannabinoid, anandamide (AEA). CBD and its enantiomer, (+)-CBD, together with seven analogues, obtained by exchanging the C-7 methyl group of CBD with a hydroxy-methyl or a carboxyl function and/or the C-5′ pentyl group with a di-methyl-heptyl (DMH) group, were tested on: (a) VR1-mediated increase in cytosolic Ca2+ concentrations in cells over-expressing human VR1; (b) [14C]-AEA uptake by RBL-2H3 cells, which is facilitated by a selective membrane transporter; and (c) [14C]-AEA hydrolysis by rat brain membranes, which is catalysed by the fatty acid amide hydrolase. Both CBD and (+)-CBD, but not the other analogues, stimulated VR1 with EC50=3.2 – 3.5 μM, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 – 70% of the effect obtained with ionomycin (4 μM). CBD (10 μM) desensitized VR1 to the action of capsaicin. The effects of maximal doses of the two compounds were not additive. (+)-5′-DMH-CBD and (+)-7-hydroxy-5′-DMH-CBD inhibited [14C]-AEA uptake (IC50=10.0 and 7.0 μM); the (−)-enantiomers were slightly less active (IC50=14.0 and 12.5 μM). CBD and (+)-CBD were also active (IC50=22.0 and 17.0 μM). CBD (IC50=27.5 μM), (+)-CBD (IC50=63.5 μM) and (−)-7-hydroxy-CBD (IC50=34 μM), but not the other analogues (IC50>100 μM), weakly inhibited [14C]-AEA hydrolysis. Only the (+)-isomers exhibited high affinity for CB1 and/or CB2 cannabinoid receptors. These findings suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues. In view of the facile high yield synthesis, and the weak affinity for CB1 and CB2 receptors, (−)-5′-DMH-CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent. British Journal of Pharmacology (2001) 134, 845–852; doi:10.1038/sj.bjp.0704327